Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini

Journal of Controlled Release

Volumn 95, Issue 3, 2004, Pages 477-488

  Gorodetsky, Raphael ^a   Levdansky, Lila ^a   Vexler, Akiva ^a   Shimeliovich, Irina ^a   Kassis, Ibrahim ^a   Ben Moshe, Matti ^b   Magdassi, Shlomo ^b   Marx, Gerard ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HAPTO Biotech Ltd   (Israel)

Author keywords

Cell membrane; DOX; Doxil; Doxorubicin; Doxorubicin loaded stealth (PEG coated) liposomes; Fibrin and or fibrinogen; Fibrin(ogen); Fibrinopeptides; FITC; Fluorescein isothiocyanate; Haptides; Liposomes; Rhodamine; Transduction

Indexed keywords

ATOMIC FORCE MICROSCOPY; CELL MEMBRANES; LIGHT SCATTERING; PARTICLE SIZE ANALYSIS; TOXICITY;

LIPOSOME TRANSDUCTION; NANOPARTICLES;

ORGANIC COMPOUNDS;

ARGINYLGLYCYLALANYLASPARTYLTYROSYLSERYLLEUCYLARGINYLALANYLVALYLARGINYLMETHI ONYLLYSYLISOLEUCYLARGINYLPROLYLLEUCYLVALYLTHREONYLGLUTAMINE; DOXORUBICIN; FIBRINOGEN; LIPOSOME; LYSYLGLYCYLSERYLTRYPTOPHYLTYROSYLSERYLMETHIONYLARGINYLLYSYLMETHIONYLSERYLME THIONYLLYSYLISOLEUCYLARGINYLPROLYLPHENYLALANYLPHENYLALANYLPROLYLGLUTAMINYLGLUTAM INE; LYSYLTHREONYLARGINYLTYROSYLTYROSYLSERYLMETHIONYLLYSYLLYSYLTHREONYLTHREONYLM ETHIONYLLYSYLISOLEUCYLISOLEUCYLPROLYLPHENYLALANYLASPARAGINYLARGINYLLEUCINE; MACROGOL; NANOPARTICLE; RHODAMINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ABSORPTION; ALPHA CHAIN; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BETA CHAIN; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DISSOLUTION; DOSE RESPONSE; DRUG FORMULATION; DRUG UPTAKE; ENDOTHELIUM CELL; FIBROBLAST; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGHT SCATTERING; NONHUMAN; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; ZETA POTENTIAL;

ANIMALS; AORTA; CATTLE; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG CARRIERS; FIBRINOGEN; FIBROBLASTS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; LIPOSOMES; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PEPTIDE FRAGMENTS; RHODAMINES;

EID: 1542719305     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.12.023     Document Type: Article

References (39)

1. Brynda E., Cepalova N.A., Stol M. Equilibrium adsorption of human serum albumin and fibrinogen on hydrophobic and hydrophilic surfaces. J. Biomed. Mater. Res. 18:1984;685-693.
2. Nygren H., Stenberg M., Karlsson C. Kinetics supramolecular structure and equilibrium properties of fibrinogen adsorption at liquid-solid interfaces. J. Biomed. Mater. Res. 26:1992;77-91.
3. Retzinger G.S., DeAnglis A.P., Patuto S.J. Adsorption of fibrinogen to droplets of liquid hydrophobic phases: functionality of the bound protein and biological implications. Arterioscler. Thromb. Vasc. Biol. 18:1998;1948-1957.
4. Retzinger G.S., DeAnglis A.P., Patuto S.J. Adsorption of fibrinogen to droplets of liquid hydrophobic phases. Functionality of the bound protein and biological implications. (see liposomes) Arterioscler. Thromb. Vasc. Biol. 18:1998;1948-1957.
5. Cunningham M.T., Citron B.A., Koerner T.A. Evidence of a phospholipid binding species within human fibrinogen preparations. Thromb. Res. 95:1999;325-334.
6. G. Marx, Biologic adhesive composition containing fibrin glue and liposomes. Methods of preparation and use, US Patent # 5,607,694 (1997).
7. Meyenburg S., Lilie H., Panzer S., Rudolph R. Fibrin encapsulated liposomes as protein delivery system: studies on the in vitro release behavior. J. Control. Release. 69:2000;159-168.
8. Nieuwenhuizen W., Mosesson M.W., DeMaat M.P.M. Fibrinogen Workshop. Ann. N.Y. Acad. Sci. vol. 936:2001;28-43.
9. Grieninger G. Contribution of the αE C domain to the structure and function of fibrinogen-420. Ann. N.Y. Acad. Sci. 936:2001;44-64.
10. Gorodetsky R., Vexler A., An J., Mou X., Marx G. Haptotactic and growth stimulatory effects of fibrin(ogen) and thrombin on cultured fibroblasts. J. Lab. Clin. Med. 131:1998;269-280.
11. Gorodetsky R., Vexler A., Shamir M., An J., Levdansky L., Shimeliovich I., Marx G. New cell attachment peptide sequences from conserved epitopes in the carboxy termini of fibrinogen. Exp. Cell Res. 287:2003;116-129.
12. Marx G., Ben-Moshe M., Magdassi S., Gorodetsky R. Fibrinogen C-terminal peptidic sequences (Haptides) modulate fibrin polymerization. Thromb. Haemost. 91:2004;43-51.
13. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethylene-glycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
14. Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta. 2(1029):1990;91-97.
15. Schiffelers R.M., Storm G., Bakker-Woudenberg I.A. Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. Int. J. Pharm. 214:2001;103-105.
16. Goren D., Gabizon A., Barenholz Y. The influence of physical characteristics of liposomes containing DOX on their pharmacological behavior. Biochim. Biophys. Acta. 1029:1990;285-294.
17. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6:2000;1949-1957.
18. Arikan S., Rex J.H. Lipid-based antifungal agents: current status. Curr. Pharm. Des. 7:2001;393-415.
19. Sundar S., Gregoriadis G. Liposomal amphotericin B. Lancet. 357(9258):2001;801-802.
20. Shaw D.T. Introduction to Colloid and Interface Science. 4th edition:1992;Butterworth, Oxford.
21. C.S. Zsiegel, E.R. Lee, D.J. Harris, Cationic lipids for intracellular delivery of biologically active molecules, US patent # 5,459,12 (1995).
22. Vivest E., Brodin P., Lebleu B. Truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:1997;16010-16017.
23. Ho A., Schwarze S.R., Mermelstein S.J., Waksman G., Dowdy S.F. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61:2001;447-474.
24. Wender P., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13003-13008.
25. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., Sugiura Y. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276:2001;5836-5840.
26. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271:1996;18188-18193.
27. Drin G., Demene H., Temsamani J., Brasseur R. Translocation of the pAntp peptide and its amphipathic analogue AP-2AL. Biochemistry. 40:2001;1824-1834.
28. Prochiantz A. Homeodomain-derived peptides. In and out of the cells. Ann. N.Y. Acad. Sci. 886:1999;172-179.
29. Morris M.C., Depollier J., Mery J., Heitz F., Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19:2001;1173-1176.
30. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57:2000;679-686.
31. Rousselle C., Smirnova M., Clair P., Lefauconnier J.M., Chavanieu A., Calas B., Scherrmann J.M., Temsamani J. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 296:2001;124-131.
32. Lundberg P., Langel U. A brief introduction to cell-penetrating peptides. J. Mol. Recognit. 16:2003;227-233.
33. Torchilin V.P., Rammohan R., Weissig V., Levchencko T.S. TAT peptide on the surface of liposomes afford their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. 98:2001;8786-8791.
34. Torchilin V.P., Levchenko T.S. TAT-liposomes: a novel intracellular drug carrier. Curr. Protin Pept. Sci. 4:2003;133-140.
35. Tseng Y.L., Liu J.J., Hong R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides and Tat: a kinetic and efficacy study. Mol. Pharmacol. 62:2002;864-872.
36. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., Sugiura Y. Arginine rich peptides, an abundant membrane permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276:2001;5836-5840.
37. Vives E. Cellular uptake of the Tat petide: an endocytosis mechanism following ionic interaction. J. Mol. Recognit. 16:2003;265-271.
38. Kim C.M., Vogel J., Jay G., Rhim J.S. The HIV tat gene transforms human keratinocytes. Oncogene. 7:1992;1525-1529.
39. H. Jia, M. Lohr, S. Jezequel, D. Davis, S. Shaikh, D. Selwood, I. Zachary. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.